When skin reactions interrupt bone therapy: severe cutaneous adverse reaction to romosozumab leading to treatment discontinuation

Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild. Case report: We present a...

Full description

Bibliographic Details

Published in:	European Journal of Case Reports in Internal Medicine
Main Authors:	Luis Antonio Rodriguez Arrieta, Paola Andrea Rueda Galvis, Miryam Vanessa Rueda Galvis, Samir Alexander Pantoja Meneses, José Manuel Yépez Rodriguez, Francisco Javier Suarez Contreras
Format:	Article
Language:	English
Published:	SMC MEDIA SRL 2025-08-01
Subjects:	adverse drug reaction romosozumab skin reactions osteoporosis monoclonal antibodies
Online Access:	https://www.ejcrim.com/index.php/EJCRIM/article/view/5719